Virtustream Announces xStreamCare Services™ for Security and Compliance, Enabling Customers to Reduce Risks and Achieve More Proactive Security Posture
9.10.2020 14:00:00 EEST | Business Wire | Press release
Virtustream, an enterprise-class cloud company and Dell Technologies business, announced xStreamCare Services for Security and Compliance today, bringing together advanced security management and monitoring, expert consulting services, and its innovative Trust Platform – a unified, security and compliance management platform.
Virtustream’s latest security solutions provide near real-time visibility into security alerts, intrusion attempts, open vulnerabilities, log analytics, policy management and entitlements across Virtustream’s Enterprise Cloud and Healthcare Cloud platforms, enabling enterprises to achieve a more proactive security posture to protect their business’ IT assets, applications and data.
“Setting the standards of excellence is important to our team at Benjamin Moore. Not only for our products and color offerings, but also for IT security,” said Syed Haider, Director of IT Security, Benjamin Moore. “Virtustream’s deep cloud expertise and focus on understanding our business’ needs make it an excellent fit for us. And by leveraging Virtustream’s new Trust Platform and comprehensive security services – with clear visibility all in one place – we can seamlessly address any issues or risks that may arise.”
For most customers, deploying security services is a manual process, typically managed through multiple platforms. This can be time-consuming, complex and expensive. Without a means to consolidate security data, enterprises struggle to identify their security, compliance and business risks as a whole. In fact, a recent study by Ponemon Institute1 found that 56% of businesses say data breaches occur because of a lack of visibility into the operations of their security programs.
“Our comprehensive approach to security is built on more than a decade of mission-critical cloud experience. With our new security offerings, you can eliminate the need to internally manage the growing number of complexities, cyberattacks and regulatory requirements,” says Pritesh Parekh, Chief Trust & Security Officer at Virtustream. “Our xStreamCare Services for Security and Compliance allow our customers to attain a more robust proactive security posture with unified, near real-time visibility, enabling them to quickly set priorities and make more informed security decisions with precision.”
Unified View Delivers Enhanced Insights and Faster Response Times
Virtustream’s Trust Platform aggregates and automates security data into a unified dashboard. The platform’s simplified and comprehensive view eliminates the need to manually aggregate and process logs from multiple tools and services by providing a clean, near real-time view of an enterprise’s security posture, compliance and risk across multiple workloads.
Virtustream’s Trust Platform is based on the company’s decade of experience securing mission-critical data and applications in the cloud. Further setting the new solution apart from other industry offerings are advanced features, including:
Alerts Dashboard: Displays security alerts with sensitivity levels that originate from Virtustream-deployed security controls with the ability to drill down, filter, and export data.
Vulnerability Dashboard: Prompts proactive protection through awareness of open vulnerabilities as well as their severity and age. Authorized users can define and manage aging and remediation policies.
Log Analytics: Enables ad-hoc queries against aggregated security and OS logs.
Policy Management: Supports customer-defined policies for managing security vulnerabilities.
Compliance Reporting: Allows on-demand download of available reports such as Type 2 SOC 2 + HITRUST with Cloud Security Alliance (CSA) Cloud Controls Matrix and Type 2 Attestation (AT-C 105 and AT-C 205) HIPAA/HITECH.
Asset Management Dashboard: Catalogs all assets in the cloud along with the status of security services.
The Trust Platform is available today on Virtustream Enterprise Cloud and Virtustream Healthcare Cloud.
Security Services for Every Businesses’ IT Needs
The combination of robust security features with actionable visibility helps block attacks proactively before they can penetrate a secure environment. Using security services for cloud-hosted mission-critical applications can also help increase the internal security operation team’s productivity. By off-loading management, internal IT teams can reduce the daily burden of managing security operations. Internal teams can also leverage on-demand access to certified cybersecurity experts and consulting services to address a range of potential internal skills gap.
The Security Essentials Bundle includes anti-virus/anti-malware, host intrusion detection system (IDS), host firewall, host file integrity monitoring, log management and vulnerability scanning. The Security Healthcare Bundle includes all services from the Essentials set as well as data at rest encryption and network intrusion detection. And the Enhanced Bundle includes all of these services along with log forwarding, network firewall policy auditor, data at rest encryption, operating system hardening scans, and SAP virus scanning services.
Find more information on Virtustream Enterprise Cloud, Virtustream Healthcare Cloud, the Trust Center, and on xStreamCare Services for Security and Compliance.
About Virtustream
Virtustream LLC, a Dell Technologies Business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies Virtustream’s xStreamCare Services™ expertise combined with the Virtustream xStream® Management Platform and Infrastructure-as-a Service (IaaS) meets the security, compliance, performance, efficiency and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
1) “The Cybersecurity Illusion: The Emperor Has No Clothes,” by Ponemon Institute, published in July 2019, cited here on Nov. 6, 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005040/en/
Contact information
For press inquiries:
See the Virtustream newsroom
Frank E. Smith
Head of Global Communications, Virtustream
Frank.E.Smith@Virtustream.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
